Evaluate the effect of bacteriophage in pressure ulcers

To evaluate the efficacy of bacteriophage therapy for management of pressure ulcers and its comparison with conventional therapy. - NIL

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/064013

Enrollment

Registered

2024-03-12

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L891- Pressure ulcer of back Health Condition 2: L893- Pressure ulcer of buttock Health Condition 3: L894- Pressure ulcer of contiguous siteof back, buttock and hip Health Condition 4: L892- Pressure ulcer of hip Health Condition 5: L898- Pressure ulcer of other site

Interventions

Intervention1: Bacteriophage: Bacteriophage cocktail 2ml of cocktail every alternate day topically for 7 days Control Intervention1: Antibiotics: Broad spectrum and empirical antibiotics

Eligibility

Inclusion criteria

Inclusion criteria: RTA resulting in head injury, spinal cord injury, polytrauma admitted in intensive care unit Grade 3 and 4 pressure ulcers

Exclusion criteria

Exclusion criteria: No consent Pregnancy and lactation Systemic diseases Dermatologic diseases Burns Malignancy Tumour Tuberculosis

Design outcomes

Primary

Measure	Time frame
Dimension of the ulcer, exudate amount and Tissue typeTimepoint: At 0, 5, 7, 14, 21, 28th day	—

Secondary

Measure	Time frame
Healing of pressure ulcerTimepoint: At 28th day	—

Countries

India

Contacts

Public ContactDr Kavita Meena

Institute of Medical Sciences, BHU, VARANASI

kvtamn68@gmail.com9711897587

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026